E. Plouvier

发表

NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology.

G. Leverger, D. Frappaz, F. Méchinaud, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup?

J. Zucker, E. Bouffet, T. Philip, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second neoplasm in children treated in EORTC 58881 trial for acute lymphoblastic malignancies: Low incidence of CNS tumours

Y. Bertrand, J. van der Werff Ten Bosch, A. Uyttebroeck, 2011, Pediatric blood & cancer.

Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia. The European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative Group.

Y. Bertrand, F. Méchinaud, S. Suciu, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

D. Blaise, H. Esperou, F. Guilhot, 2003, Bone Marrow Transplantation.

High-dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: an unselected group of stage IV patients over 1 year of age.

J. Zucker, T. Philip, P. Bordigoni, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bone marrow transplantation (BMT) in 14 children with severe sickle cell disease (SCD): the French experience. GEGMO.

S. Lemerle, P. Bordigoni, P. Lutz, 1993, Bone marrow transplantation.

Juvenile myelomonocytic leukemia: analyses of treatment results in the EORTC Children's Leukemia Cooperative Group (CLCG).

Y. Bertrand, C. Rubie, P. Lutz, 1996, Bone marrow transplantation.

Long‐term renal and hearing toxicity of carboplatin in infants treated for localized and unresectable neuroblastoma: Results of the SFOP NBL90 study

P. Froehlich, C. Bergeron, E. Plouvier, 2005, Pediatric blood & cancer.

Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group.

H. Cavé, Y. Bertrand, M. Fournier, 2000, Leukemia.

In vivo infusion of anti-LFA-1 and anti-CD2 antibodies prevents graft failure after HLA partially incompatible bone marrow transplantation in children with high risk acute lymphoblastic leukaemia.

A. Fischer, A. Baruchel, E. Haddad, 1997, Leukemia & lymphoma.

Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report

Y. Bertrand, A. Uyttebroeck, S. Suciu, 2005, Leukemia.

Late thyroid toxicity in 153 long-term survivors of allogeneic bone marrow transplantation for acute lymphoblastic leukaemia

J. Stéphan, C. Berger, J. Donadieu, 2005, Bone Marrow Transplantation.

Metastatic neuroblastoma in children older than one year old at diagnosis. Treatment with intensive chemo-radiotherapy and autologous bone marrow transplant.

J. Zucker, T. Philip, P. Bordigoni, 1985, Revue francaise de transfusion et immuno-hematologie.

PURGED AUTOLOGOUS BONE MARROW TRANSPLANTATION IN 25 CASES OF VERY POOR PROGNOSIS NEUROBLASTOMA

J. Zucker, M. Favrot, J. Kemshead, 1985, The Lancet.

A phase II trial of partially incompatible bone marrow transplantation for high‐risk acute lymphoblastic leukaemia in children: prevention of graft rejection with anti‐LFA‐1 and anti‐CD2 antibodies

A. Baruchel, M. Cavazzana‐Calvo, B. Lacour, 1996 .

Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.

N. Dastugue, A. Uyttebroeck, S. Suciu, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report

H. Cavé, Y. Bertrand, M. Fournier, 2000, Leukemia.

The TAM regimen prior to allogeneic and autologous bone marrow transplantation for high-risk acute lymphoblastic leukemias: a cooperative study of 62 patients.

J. Bergerat, J. Reiffers, P. Colombat, 1991, Bone marrow transplantation.

Cutaneous involvement in children with acute lymphoblastic leukemia or lymphoblastic lymphoma. The Children's Leukemia Cooperative Group of the European Organization of Research and Treatment of Cancer (EORTC).

P. Rohrlich, Y. Bertrand, F. Guilhot, 1997, Pediatrics.

The role of BMT for neuroblastoma relapse patients. A report of the EBMT-STR.

D. Frappaz, J. Zucker, F. Chauvin, 1991, Bone marrow transplantation.

LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis.

D. Frappaz, V. Combaret, J. Stéphan, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1-11 Trial of a Monoclonal Anti-Tumor Necrosis Factor a Antibody for the Treatment of Refractory Severe Acute Graft-Versus-Host Disease

P. Tiberghien, J. Stéphan, E. Holler, 2003 .

CLIO: Collaboration for an infrared laser at Orsay

Y. Thiery, P. Brunet, A. Dael, 1989 .

Treatment outcome in infant acute lymphoblastic leukemia. Children Leukemia Cooperative Group--EORTC. European Organization for Research and Treatment of Cancer.

A. Uyttebroeck, S. Suciu, Y. Benoît, 2000, Blood.

Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG

P. Maes, Y. Bertrand, J. van der Werff Ten Bosch, 2005, Leukemia.

IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951

E. Clappier, H. Cavé, P. Kastner, 2015, Leukemia.

Treatment of acute lymphoblastic leukemia in children with the BFM protocol. A cooperative pilot study.

Y. Benoît, G. Solbu, P. Lutz, 1987, The American journal of pediatric hematology/oncology.